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1. SUMMARY 
Substantial evidence suggests that the presence of immune cells, 
including Natural Killer cells (NKs), plays a crucial role in the 
development and/or progression of human tumors. NKs are effector 
lymphocytes of innate immunity, primarily involved in 
immunosurveillance against tumors through their cytotoxic activity. 
However, our previous study demonstrated that NKs are directly involved 
in inducing tumor angiogenesis in non small cell lung cancer (NSCLC). 
CD56brightCD16- NK cells infiltrating resectable tumors (TINKs), and 
even peripheral blood NK cells (TANKs) from patients with NSCLC are 
able to produce pro-angiogenic cytokines, including VEGF, PlGF and IL-
8 showing a decidual-like phenotype. 
Here, we aimed at extending our findings to colorectal carcinoma (CRC), 
to verify whether the TINK/TANK polarization occurs also in CRC 
patients and may represent a crucial feature of solid tumors. 
To address our study, we performed multicolor flow cytometry, using 
NKs derived from peripheral blood and tissue samples of CRC patients 
compared with NKs derived from healthy controls’ peripheral blood. 
Conditioned media (CM) from FACS-sorted NKs were used either for 
secretomic profiling, by antibody membrane array or angiogenesis 
functional assay on human umbilical endothelial vein cells (HUVECs).  
We found that CD56brightCD16- NK cells predominate in CRC adjacent 
and tumor tissues, produce VEGF, PlGF, IL-8 and show impaired 
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cytotoxicity. Further, TINK/TANKs from CRC patients express the 
decidual NK markers CD9 and CD49a, supporting the hypothesis of a 
pro-angiogenic polarization. Secretomic analysis on CRC peripheral 
blood NKs revealed the up-regulation of several factors, including 
Angiogenin, Angiopoietin-1/2, TIMP-1/2, VEGF, IL-8, MMP9 and MCP-
1. The activation of STAT-3 and STAT-5 pathways were observed in 
TANKs, suggesting a potential involvement of these signaling pathways 
in NK mediated induction of angiogenesis. We also demonstrated that 
conditioned media by FACS sorted NK cells from peripheral blood and 
tumor tissue of CRC patients could induce HUVEC proliferation, 
migration, adhesion and the formation of capillary like structures. These 
functional data are associated with molecular changes in HUVECs 
induced by NK conditioned media, that include the phosphorylation of 
AMP-activated protein kinase α (AMPKα), Glycogen Synthase Kinase 
3β, P70 S6 Kinase and S6 ribosomal proteins. 
Taken together, our data demonstrate that TINK/TANKS from CRC 
patients are switched toward a pro-angiogenic/pro-tumor phenotype and 
function. We propose that TINK/TANKs could represent the hallmark for 
a new paradigm in CRC inflammation. 
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2. INTRODUCTION 
2.1 Natural Killer cells (NKs) 
 
Natural killer (NK) cells were first discovered in 1975 by Kiessling and 
Herberman [1]. They belong to innate immunity, due to their ability to 
recognize and rapidly kill target cells without a prior sensitization [2]. 
Recently, NK cells have been classified as members of a specialized 
cohort of leukocytes, termed Innate Lymphoid Cells (ILCs) [3]. These 
cells have been distinguished from B and T lymphocytes based on their 
lack of immunoglobulin and T cell receptors, which are the result of 
somatic gene rearrangements [3]. Three groups of ILC have been 
recognized on the basis of their cytokine expression patterns and 
dependency on transcription factors (Figure 1):  i) IFN-γ producing cells 
are defined as ILC1, which originally included NK cells and further 
distinguished from them due to the expression of CD127 (IL-7Ra) and T-
bet transcription factor; ii) NK cells which depend mainly on the EOMES 
transcription factor and exert granule-dependent cell cytotoxicity ILC-2 
which produce type 2 cytokine and need GATA-binding protein 3 
(GATA3) and retinoic acid receptor-related orphan receptor-α (RORα) for 
their development and functions; iii) ILC3 which depend on the RORγt 
transcription factor for their development and functions and are able to 
release IL-17 and/or IL-22 [3].  
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Adapted from Spits H et al, Nat Rev Immunol. 2013 
 
 
2.1.1 NK cell origin and development  
NK cell development is characterized by numerous differentiation 
and maturation steps (Figure 2). NK cells originate from the CD34+ 
hematopoietic progenitor cells (HPCs) located in the bone marrow even if 
recent data support the idea that NK cell development is not completely 
restricted to bone marrow [4]. A small population of NK cells described 
Figure	 1	 –	 ILCs	 family:	 different	 groups	 for	 different	 functions.	 ILC	 cells	 are	conventionally	divided	in	three	groups,	based	on	the	expression	of	different	transcription	factors	and	cytokine	release. 
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as CD56bright NK cells has been reported to originate from hematopoietic 
precursor cells in the lymph nodes [5]. The developing decidua, the 
uterine lining during pregnancy, contains hematopoietic precursors from 
which decidual NK cells (dNKs) might originate [6]. NK cells have been 
also proposed to develop in the liver, explaining the presence of immature 
NK cells in adult livers [2]. A recent study suggested that NK cells could 
also derive from a myeloid precursor [7]. Since these findings are not 
completely confirmed, up to date we assume that NK cells develop from a 
common lymphoid progenitor (CPL) from which NK, B and T cells 
originate. During the first step of differentiation, the formation of a 
bipotent NK/T progenitor occurs, which originates NK and T cells [8]. 
The acquisition of the β subunit of IL-15R, also termed CD122, 
represents the most relevant event that characterizes the generation of NK 
cell precursors that acquire the ability to bind IL-2 and/or IL-15, relevant 
cytokines involved not only in NK cell differentiation and maturation, but 
also in their survival [9]. During the process of maturation from NK cell 
precursors to immature NK cells, several growth factor receptors, as 
FMS-like tyrosine kinase 3 (FLT3) and IL-7Rα, are down-regulated while 
IL-2Rβ, CD2 and 2B4 are up-regulated [8]. The acquisition of NK 
activatory and inhibitory receptors and the activation of specific 
transcription factors, including ID2, ID3 and E4BP4, allow the 
progression from immature to mature NK cells [8].  During the last 
phases of maturation, NK cells are educated to recognize self-molecules. 
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In particular, the education process enables NK cells to distinguish 
between MHC class I bearing cells and those with lack of expression or 
altered MHC class I molecules that will be recognized and specifically 
killed [8]. 
 
Adapted from Colucci F et al, Nat Rev Immunol 2003 
 
2.1.2 NK cell subsets 
Human NK cells represent 5-15% of peripheral blood 
lymphocytes [4]. Human NK cells are generally defined by the expression 
of two surface markers, the CD3 (cluster of differentiation 3), a T-cell co-
receptor that is involved in T-Cell cytotoxicity activation and CD56, 
which represents an adhesion molecule, in particular an isoform of the 
human neural cell adhesion molecule [4]. NK cells are described as CD3-
Figure 2 –NK cell development and maturation in the bone marrow.	Through the acquisition 
of typical NK cell markers, NK cell precursors generate immature NK cells and then mature NK 
cells.  
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CD56+ cells.  
A part from CD56 expression, human NK cells are classified based on 
CD16 surface antigen expression, a molecule belonging to the Ig 
superfamily that is a receptor for the constant portion of Ig heavy chains. 
CD16 is involved in the process of antibody-dependent cellular 
cytotoxicity (ADCC). CD16 expression correlates with different NK cell 
activities [4].  
Peripheral NK cells are predominantly CD3-CD56dimCD16+ cytotoxic NK 
cells, representing 90-95% of total NKs. They can release perforin, a β-
pore forming toxin, and granzyme, an apoptotic cascade activator. They 
can also release cytokines for a brief period [10]. A minor (5-10%) 
counterpart of circulating NK cells is represented by CD3-
CD56brightCD16- that produce high levels of some cytokines over the long 
term. Upon activation, these NK cells release IFN-γ and TNFα, and they 
kill target cells more efficiently [10]. A third distinctive NK subset has 
been characterized during the decidualization process, termed decidual 
NK cells (dNKs) [11]. This subset, which described as 
CD56superbrightCD16- [12] releases large amounts of pro-angiogenic 
factors, including VEGF, PLGF, IL-8, and represents up to the 50% of 
total lymphocytes within the decidua. These dNKs play a crucial role in 
the modulation of maternal tolerance to an allogeneic fetus, further 
sustaining the angiogenic process necessary for implantation and the 
correct formation of spiral arteries [11] (Figure 3C). This is a clear 
example of “killers” that within a peculiar environment acquire “builder” 
functions. 
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Figure 3 -  Different NK cell subsets. Three different NK subset have been characterized, on the 
basis of distinctive surface antigen expression and described as A) CD56dimCD16+, that represents 
the conventional cytotoxic NKs, characterized by a low production of cytokines and a high release 
of perforin and granzymes; B) CD56brightCD16-, that are able to release a large amount of 
cytokines; C) CD56superbrightCD16-, that are observed in the process of decidualization and are also 
termed decidual NK (dNKs), which produce physiologically pro-angiogenic factors, including 
VEGF, IL-8 and SDF-1 and are characterized by the expression of specific surface markers as 
CD9 and CD49a.	 
 
NK cells express a variety of activating and inhibitory receptors (listed in 
Figure 4) that can modulate NK functions by stimulating or damping their 
responses. These molecules allow a subtle regulation of NK that lead to a 
balance between activating versus inhibitory signals [4]. Five classes of 
NK receptors have been identified and described as activating receptors, 
cytokine receptors and adhesion receptors, that are mainly involved in NK 
cell activation in terms of cytolytic activity and cytokine production. 
Chemotactic receptors promote NK cell recruitment to inflamed tissues, 
whereas inhibitory receptors mediate NK cell dampening [4]. 
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Adapted from Vivier E. et al, Science 2011 
 
CD56dim NK cells showed high levels of KIRs (Killer-cell 
Immunoglobulin-like Receptors) that exert mostly inhibitory effects, but 
low levels of CD94/NKG2 activatory receptors. On the contrary, 
CD56bright NK cells show low to absent KIR levels and largely express 
CD94/NKG2A receptors [13]. Although CD56bright and CD56dim NK cells 
are comparable in terms of NKG2D expression [14] they differ in terms 
of NKp46 expression, which results higher in the CD56bright subset [15]. 
 
Figure 4 - NK cell receptor repertoire. Five different classes of receptors have been identified 
on NK cells, including activating receptors, cytokine receptors and adhesion receptors that are 
mainly involved in NK cell activation towards target cells. Chemotactic receptors promote NK 
cell recruitment. Inhibitory receptors mediate NK cell dampening.	
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2.2 NK cells and cancer progression 
2.2.1 NK and tumor cells 
Several in vitro and in vivo studies have shown that NK cells play a 
relevant role in cancer progression and patient outcome [16-19]. Cancer 
patients which display high numbers of tumor infiltrating NK cell have 
been reported to display a better prognosis [20] even if an impairment of 
their activities is correlated with an increased risk to develop cancer. This 
was demonstrated in gastric carcinoma, where a high percentage of NK 
cell infiltration is associated to a reduction of tumor invasion and lymph 
node metastasis [21]. In lung cancer, the presence of tumor-infiltrating 
CD11b-CD27- NK cells positively correlated with the tumor stage and 
tumor size [22]. Carrega et al showed that NK cells isolated from lung 
cancer tissues display lower cytolytic potential as compared with NK 
cells from peripheral blood or normal lung tissue, even if no difference 
was observed in term of cytokine production including TNF-α and IFN-γ 
[16]. In addition, it has been reported that NK cells are particularly 
involved in limiting tumor metastasis pulmonary, melanoma metastasis 
and colorectal adenocarcinoma and peritoneal dissemination [23]. Since 
NK cells can recognize and kill tumor cells, several studies were 
performed to clarify mechanisms underlying this process. As previously 
described, several inhibitory receptors are expressed by NK cells able to 
bind MHC class I molecules. Therefore, NK cells can discriminate 
between self and non-self cells. During maturation phases, NK cells are 
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“educated”: NK inhibitory receptor repertoire is adapted to the MHC 
class I molecules borne by the host, assuring NK cell tolerance against 
self-cells. On the other hand, NK cell are simultaneously stimulated by 
activatory receptors, which trigger NK responses. In the presence of 
healthy cells, activatory signals are low, thus the binding of inhibitory 
receptors to MHC class I molecules is sufficient to induce NK cell 
tolerance (Figure 5). On the contrary, NK are able to recognize altered 
cells (i.e. tumor cells) that lack MHC I expression which are recognized 
and killed; cells expressing high levels of stress-induced ligands, even in 
the presence of inhibitory ligands, can be lysed if the activatory signals 
overcome the inhibitory ones (Figure 5) [24]. The anti-tumor activities of 
NK cell are not restricted to perforin and granzyme release, but include 
also cytokine production, and IFN-γ secretion [25].  
 
Adapted from Bruno et al, J Natl Cancer Inst. 2014 
Figure 5 - Tumor cell-mediated activation of NK cells. Three are the main mechanisms by which 
NK cells recognize target cells. A) Healthy cells that express MHC class I molecules induce NK 
cell tolerance. B) Tumor cells which lack MHC I expression are recognized and killed. C) The 
expression of stress-induced ligands together with the lacking of MHC class I molecules by tumor 
cells favor NK cell activation.  
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NK cell infiltrate has been observed in several types of solid malignances 
including melanoma [26], gastro-intestinal stromal tumors (GIST) [27], 
colorectal [28], renal[29], lung [30, 31], and breast cancers [32] (Figure 
6). One of the major concerns regarding the role of NK cells in tumor 
progression is represented by the low percentage of tumor infiltrating NK 
cells (TINKs). Indeed, several studies in different cancer types 
(colorectal, lung) have shown that NK cells are mostly found around 
blood vessels and do not co-localize with tumor cells [31]. NKs 
infiltrating solid cancers have been reported to be predominately 
CD56bright (Figure 6 and 7) [16, 30].  
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Adapted from Cantoni et al, J Immunol Res. 2016 
 
Figure 6 – Tumor infiltrating NKs in solid malignancies - low percentage of tumor infiltrating 
NK cells has been reported in several solid cancers. 
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In the last decade, several studies have demonstrated that cancer 
cells are able to decrease NK recruitment and impair NK cell anti-tumor 
activities, promoting the “tumor escape phenomenon” [33]. By inhibiting 
NK cell recruitment, tumor cells prevent NK cell cytotoxic functions. In 
addition, tumor cells could also down-regulate the expression of NK 
activatory receptors, promoting their desensitization, tumor 
immunotolerance and promote the induction and the release of immuno-
suppressive microenvironment by producing TGF-β and IL-10, finally 
dampening NK cell response [34]. The ability of tumor cells to attenuate 
NK anti-tumor activity and enhance pro-tumor properties is a crucial 
phenomenon, termed “polarization” (Figure 7). Given their plasticity, 
diverse cell of the immune system, both of innate and adaptive immunity, 
have been described to acquire pro-tumor/pro-angiogenic phenotype and 
functions. Macrophages represent the most characterized immune cell 
component in this scenario. Studies on NK cell polarization are still few 
in the literature and the major of them are focused on NK anergy and 
impaired toxicity [16-19, 22]. The first study in investigating the 
contribution of NK cells to tumor progression by sustaining angiogenesis 
was done in non small cell lung cancer (NSCLC) [30, 33]. The NK cells 
infiltrating tumors were termed tumor infiltrating NK cells (TINKs), 
while peripheral blood NK cells were termed tumor associated NK cells 
(TANKs) [30, 33]. 
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2.2.2 NK and angiogenesis 
Angiogenesis, i.e. the formation of new blood vessels, represents a 
necessary process in a wide number of physiological (reproduction, 
development, tissue repair and wound healing) events and pathological 
conditions, including neurodegenerative diseases, diabetes and cancer 
[35]. NK cell contribution to angiogenesis has been reported in different 
contexts [33]. As previously described, a peculiar CD56superbrightCD16- 
NK subset found in the decidua during implantation acquires low 
cytotoxic and high pro-angiogenic activities [36, 37]. NK cells have also 
been reported to correlate with angiogenesis during tissue repair process 
in c-kit deficient mice [38]. Further analyses showed that lectin-like 
receptor 1+ and α4β7 integrin+ NK cells were required for angiogenesis in 
the damaged murine myocardium [39]. In models of bFGF (basic-
fibroblast growth factor)-induced corneal and laser-induced choroidal 
angiogenesis, a reduction of NK infiltrate, led to a significant of decrease 
of neovascularization[40].  
To date, studies investigating the direct contribution of NK cells in 
promoting angiogenesis have been mostly addressed on the 
cardiovascular implications of myocardial NK cells, or on ocular NK 
properties and on dNK cells, as reported in Figure 7 [30]. Regarding the 
role of NK cells in sustaining tumor angiogenesis, very few studies have 
focused their attention on the link between tumor NK infiltrate and vessel 
density [33]. Previous findings by our lab in the non small cell lung 
cancer (NSCLC) context have shown that the major NK subset in NSCLC 
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tissues is the decidual-like CD56brightCD16- [30]. When examined for 
angiogenic cytokine production it was showed that TANKs from 
squamous cell carcinoma patients produced substantially higher levels of 
VEGF and PlGF as compared with those of adenocarcinomas that 
resulted comparable with those from healthy controls [30]. NSCLC 
TINKs showed angiogenesis-associated activities in vitro, inducing the 
formation of capillary-like structure by endothelial cells and promoting 
their migration [30]. 
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Adapted from Bruno et al, J Natl Cancer Inst. 2014 
 
 
Figure 7 - Studies that have focused on the pro-angiogenic and pro-tumor role of Natural 
Killer cells. Several studies have investigated the role of NK in tumor progression and in 
angiogenesis. Most them, addressed their attention on decidual NK or the cardiovascular 
compartment. Only few studies have evaluated the role of NK in tumor associated angiogenesis.  
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Recently, Gotthard et al. highlighted the relationship between NKs and 
angiogenesis, demonstrating that Stat5∆/∆Ncr1-iCreTg-Vav-Bcl2 mice 
failed to control tumor growth of RMA-S lymphoma cells and a v-abl 
transformed tumor clarifying the significant tumor- promoting function of 
STAT5-deficient NK cells [41]. Analyzing the levels of proangiogenic 
factors in this murine model, they observed an increased VEGF 
production by STAT5-deficient NK cells. To elucidate the role of VEGF 
production in NKp46+ cells, Gotthardt and colleagues established 
Vegfa∆/∆Ncr1-iCreTg mice, characterized by NKp46+VEGF- cells. By 
using different tumor models (v-abl+ tumor, RMA-S, and A-MuLV–
induced leukemia), they showed a significant reduction of tumor burden 
and fewer CD31+ blood vessels in tumors [41, 42]. 
 
2.2.3 Clinical and preclinical anti-cancer therapies able to modulate 
NK activity  
Several targets of current anti-cancer therapies are expressed by tumor 
cells as well as immune cells. Therefore, few treatments not only impact 
on cancer cell survival and proliferation but also influence the immune 
system activity [43]. It has been demonstrated that radiotherapy or 
chemotherapy, including arabinofuranosyl cytidine (Ara-C), cisplatin, or 
5-fluorouracil (5-FU), can increase the expression of some NK cell 
activating ligands enhancing NK cell recognition and killing [44].  
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More recently, several target therapies have been demonstrated to 
improve NK cell-mediated tumor killing [45, 46]. The proteasome 
inhibitor bortezomib induced the expression of ligands of NK cell 
activating receptors. Lenalidomide, an anti-angiogenic drug, modulates 
the immune response indirectly by enhancing tumor cell ligands and 
inducing the expression of NK cell stimulatory cytokines (i.e. T cell 
derived IL-2) or directly by lowering the threshold for NK cell activation 
[47, 48]. 
During the last years, several studies have also focused their attention to 
checkpoint inhibitors as one of the most promising approach among 
immunotherapies. It has been demonstrated that treatments with anti-
CTLA4 or anti-PD-1 antibodies can restore T cell activity in cancer 
patients resulting in tumor regression in some patients [43]. Benson et al 
also showed that NK cells from multiple myeloma and renal carcinoma 
patients expressed PD-1 on their surface and CT-011, a novel anti-PD-1 
antibody, is able to enhance human NK-cell function against autologous, 
primary MM cells [49].  
 
2.3 Colorectal Cancer 
2.3.1 Epidemiology and pathologic features of Colorectal Cancer 
(CRC) 
Colorectal cancer (CRC) represents the third most common cancer 
in men (746,000 cases, 10.0% of all cancers in men worldwide) and the 
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second most common cancer in women (614,000 cases, 9.2% of all 
cancers in women worldwide) [50].  Regarding incidence and mortality 
rates, there is a marked variation across countries and regions [51]. 
Eastern Europe and Asia have observed an enhancement of incidence 
rates that have been attributed to behavioral risk factors related to diet and 
lifestyle. Some countries, including Brazil, Mexico, and Romania have 
observed increasing CRC mortality rates that might be correlated with the 
limited healthcare resources [51]. 
The World Health Organization (WHO) distinguished a wide number of 
CRC histological variants that includes mucinous adenocarcinomas, 
signet ring cell adenocarcinomas, medullary, micropapillary, serrated, 
cribriform comedo-type, adenosquamous, spindle cell, and 
undifferentiated [52]. Mucinous adenocarcinomas are defined by >50% of 
the tumor volume composed of extracellular mucin and are characterized 
by large glandular structures with pools of extracellular mucin. The most 
of mucinous adenocarcinomas occurs in patients with hereditary 
nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) with high- 
levels of microsatellite instability (MSI-H), while mucinous 
adenocarcinomas that present microsatellite stability (MSS) are reported 
to be more aggressive [53]. Signet ring cell adenocarcinomas are rare in 
the colorectum, representing only 1% of all colorectal carcinomas and are 
defined by the presence of >50% of tumor cells showing signet ring cell 
features characterized by a prominent intracytoplasmic mucin vacuole. 
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Conventionally, signet ring cell carcinoma are poorly differentiated (high 
grade) even if some of them can be MSI-H tumors displaying a lower 
grade [54]. Medullary carcinomas are extremely rare (5-8 cases for every 
10,000 colorectal cancers) characterized by sheets of epithelioid 
neoplastic cells with large vesicular nuclei, prominent nucleoli, and 
abundant cytoplasm and is strongly associated with MSI-H. It usually has 
a favorable prognosis despite its poorly differentiated or undifferentiated 
histology [55]. 
Randomized controlled trials (RCT) have shown that screening is 
associated with a reduction in CRC mortality. Indeed, CRC incidence and 
mortality rates have been declining in the United States and other high-
incoming countries due to the introduction of screening programs that 
enables primary prevention and early detection [50, 51]. During the last 
decade, technological advances have led to the development of new, less 
invasive screening approaches, including fecal immunochemical testing, 
computed tomographic colonography (CTC), stool DNA testing, and 
colon capsule endoscopy [51]. In addition, several studies focused their 
attention in order to identify possible non-invasive biomarkers (blood- or 
stool-based markers) for early detection of CRC able to ameliorate CRC 
diagnosis, improve patient prognosis, prediction of treatment response, 
and possible prediction of recurrence risk [56].  
The immune contexture (including type, density, and location of immune 
cells within the tumor samples) of tumor microenvironment has been 
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shown to influence tumor progression determining the fate and survival of 
the patient and the response to therapy. Thus, several studies have focused 
on novel and non-invasive prognostic tools able to measure in situ 
immune cell infiltrates. The immunoscore, a scoring system based on the 
quantitated numbers of cytotoxic and memory T cells infiltrating the core 
of the tumor and its invasive margins, revealed the major positive role of 
these cells for patient’s survival, suggesting its potential application as a 
biomarker for the prediction of prognosis and response to therapy [57] 
(Figure 8). In CRC context, an Immunoscore based on the combined 
analysis of CD8+ plus CD45RO+ cells in specific tumor regions has been 
shown as a relevant tool to predict tumor recurrence and survival in 
patients with early-stage (AJCC/UICC-TNM stages I and II) CRC. 
Moreover, considering the disease-specific survival according to CD8+ 
and CD45RO+ densities in combined tumor regions (central 
tumor/invasive margin, CT/IM), the scoring system allows the 
discrimination between patients’ subgroups characterized by distinct 
clinical outcomes in terms of disease-free survival and overall survival  
[58]. The relevance of the localized immune reaction in predicting 
recurrence and survival in patients with early-stage colorectal carcinoma 
has also been assessed [59].  
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Adapted from Aghagolzadeh P et al, World J Gastroenterol. 2016 
 
 
 
2.3.2. Colorectal cancer and NKs 
It is now clear that chronic inflammation represents an hallmark of 
cancer [60] and a key risk factor for CRC development [61-63]. The use 
of anti-inflammatory agents has been associated with a decreased CRC 
incidence [64]. On the contrary, some studies have demonstrated that an 
increased percentage of immune cell infiltration represents a good 
Figure 8 - CRC Biomarkers – Several studies have focused on the identification of novel and non-
invasive biomarker discovery for CRC based on the personalized genotype and clinical information that 
might facilitate the classification of patients to improve early detection and ameliorate patients’ 
outcome. 
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prognostic factor for clinical outcome [57, 65], suggesting a controversial 
role of immune cell infiltration in CRC.  
However, given the strong correlation between colorectal cancer and 
inflammation, several studies during the last decades have deepened the 
contribution of the diverse immune cell types in the CRC progression [66, 
67]. Tumor associated macrophages (TAMs) contribution to colon cancer 
depends on their polarization state: peri-tumor M1 macrophages [68] 
(TAM1) are able to prevent tumor development whereas M2 polarization 
[69] (TAM2) appears to be associated with cancer promotion by 
increasing of pro-tumor factors. TAM2 released IL-1β increases HIF 
production and activates NF-κB-dependent PDK1/AKT pathway in tumor 
cells, inactivates GSK3β and enhances Wnt signaling leading to colon 
cancer cell growth [70, 71].  
NK cells have been found as a minor component in the overall CRC 
inflammatory infiltrate the CRC tissues [28, 62]. Halama et. al have 
investigated NK percentage in CRC tissues, performing a quantification 
of infiltrating NK and T cells as far as the chemokine/cytokine related 
production in colon cancer biopsies, adjacent-normal and tumor tissues 
and liver metastases. The data obtained with this study clearly indicated 
that despite high levels of chemokines, the number of NK cells was 
limited within CRC biopsies, suggesting that cytokine production was 
mainly due to T cell infiltrate. On the contrary, NK percentage in adjacent 
normal tissues was significantly higher than in CRC tissues [72].  
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However, other studies demonstrated that, despite their low number in 
tumor tissues, CRC infiltrating NKs can influence patient outcome [62, 
73]. Sconocchia et al demonstrated a significant cross talk between intra-
tumor NK cell infiltration and T lymphocytes within CRC, showing that 
NKs positively influenced the clinical outcome of CRC patients by 
enhancing the protective role of tumor-infiltrating CD8+ T cell [62]. 
Rocca et al characterized tumor infiltrating NKs in CRC tissues and 
peripheral blood (PB), demonstrating a relevant alteration of their 
phenotype, with a significant down-regulation of several receptors, 
including CD16, NKG2D, NKp30, NKp44, NKp46, CD161 and DNAM-
1 [74]. They also observed an impairment of CRC and PB NK functions, 
including their ability to activate degranulation and IFN-γ production 
[74]. Performing co-culture experiments, they also demonstrated that 
phenotypic modulation and functional impairment of NK cytotoxic 
properties was promoted by cancer cells, supporting the hypothesis of the 
pro-tumor polarization induced by cancer cells on NKs [74]. 
	 
 
 
 
 
 
 
 
 
Aim of the study 
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3. AIM OF THE STUDY 
Substantial evidence suggests that the presence of immune cells plays a 
crucial role in the development and/or progression of human tumors. CRC 
represents an extremely heterogenic “scenario” where several “actors” 
interact with each other. In the tumor microenvironment (TME) context, 
immune cells can be considered a “double edged sword” that can either 
destroy tumor cells or promote tumor growth and dissemination according 
to their polarization state. Recently we have identified a new NK subset in 
non small cell lung cancer patients (NSCLC), characterized by a decidual-
like CD56brightCD16-VEGFhighPlGFhighIL-8+IFNglow phenotype, that we 
termed tumor infiltrating (TINKs) and tumor associated NKs (TANKs). 
Based on these results, we are now interested in extending our findings in 
colorectal carcinoma to: 
1. Evaluate whether the same TINK/TANK polarization also occurs 
in CRC patients. 
2. To confirm the presence of a predominant CD56brightCD16-
NKG2D- phenotype in CRC NK cells that has been already 
described in literature. 
3. Analyze cytokines production by NK cells isolated from CRC 
patients and clarify their contribution in tumor angiogenesis 
induction. 
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4. Evaluate the possible to employ TINK/TANKs as CRC 
biomarkers. 
	 
 
 
 
 
 
 
 
 
 
Material and Methods 
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4. MATERIALS AND METHODS 
4.1 Samples selection and patients’ characteristics 
Samples, including peripheral blood (PB), tumor tissues (TUM) 
and normal adjacent tissues (ADJ) were obtained from CRC patients upon 
informed consent in an institutional ethics committee approved study in 
collaboration with the Ospedale di Circolo di Varese. Tissue samples, 
after surgical resection, were maintained in PBS 1X (Sigma-Aldrich, St 
Louis, MO) with 1% penicillin/streptomycin (Sigma-Aldrich) while 15-
20 ml of PB samples were drawn from the same patients before surgical 
intervention into heparinized blood collection tubes. All samples were 
stored at 4°C before processing. Patients with diabetes, human 
immunodeficiency virus (HIV)/hepatitis C virus (HCV)/hepatitis B virus 
(HBV) infection and chronic inflammatory conditions are excluded. 
Patients previously treated with chemotherapy or radiotherapy, or those 
iatrogenically immunosuppressed or having undergone myeloablative 
therapies were also excluded from the study. Our cohort included 6 
patients with non-oncologic bowel disease (diverticular diseases – Table 
1) and 57 oncologic patients with colorectal cancer, whose characteristics 
are summarized in Table 2. Peripheral blood samples from age-matched 
healthy donors (HC) were used as controls.  
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A) 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
Table 1 – Clinical characteristics of A) healthy controls and B) non oncologic  patients. 
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Table 2A – Clinical characteristics of CRC patients included in our study 
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Table 2B – Clinical characteristics of CRC patients included in our study 
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 Table 2C – Clinical characteristics of CRC patients included in our study 
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4.2 Isolation of Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) were obtained by 
diluting whole blood samples, either from CRC patients, patients with 
diverticulosis or healthy controls, 1:2 with PBS 1X and subsequently 
subjected to a density gradient stratification. Briefly, diluted whole blood 
samples was carefully layered onto Histopaque-1077 Ficoll (Sigma-
Aldrich) and centrifuged at 500 x g for 30 minutes at room temperature 
without brake. Finally, the lymphocyte-enriched ring at the interface was 
transferred into a new collection tube and washed with PBS 1X by 
centrifugation at 250 x g for 5 minutes.  
4.3 Solid Tissue Enzymatic Digestion 
Biopsies (TUM and ADJ) were extensively washed in PBS 1X to 
remove residual red blood cells, debris and dead cells. Necrotic tissue and 
areas occupied by adipose tissue were removed using scissors. Tissues 
were then mechanically dissociated with scissors to obtain small 
fragments further subjected to enzymatic digestions for 1 hour at 37°C, 
using a cocktail containing Collagenase type II (2 mg/mL, Sigma 
Aldrich). The total cell suspension obtained was then filtered through 40 
µm cell strainers (Becton Dickinson (BD) San Jose, CA), then washed 
twice by centrifugation in RPMI 1640 (EuroClone, Milan, MI) with 10% 
FBS (Sigma Aldrich), 1% glutamine Gln, 1% Pen/Strep to remove 
residual enzymes. 
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4.4 TINK/TANK isolation and culture 
Natural Killer (NK) cells were isolated from PBMCs obtained 
from PB and biopsies as previously described by using a 3 laser FACS-
Aria II BD sorting device. Briefly, cell suspension was incubated with a 
cocktail of antibodies that included: FITC-CD45/APC-CD14, PerCP-
CD3, APC-CD56 (all purchased by Miltenyi Biotec, Auburn, CA) and 
PE-RORγt (R&D System, Minneapolis, MN) for ADJ and TUM derived 
cells (Figure 9). For secretomic analyses, immunoblotting and functional 
assays, the purity of the NK isolated cells was always verified by FACS.  
 
Figure 9 – Gating strategy for NK selection from peripheral blood (PB), adjacent normal tissue 
(ADJ) and tumor tissue (TUM). Following FSC/SSC physical parameter setting, total NKs were 
identified as CD45+CD14-CD3-CD56+ cells (A-C). For tissue samples (B,C), a further step for NK 
identification was performed by RoRyt+ cell exclusion from CD45+CD14-CD3-CD56+ cells.  
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4.5 Phenotype and Functional Characterization of TINK/TANK from 
CRC patients 
To assess NK cell subset distribution, 2.5x105 PBMCs from PB 
(HC and patients), TUM and ADJ tissues were stained for 30 minutes at 
4°C with monoclonal antibodies (mAbs) in a direct immunofluorescence 
assay and assessed by flow cytometry (FACS Canto I; BD), as follows: 
FITC-CD45/APC-CD14, PerCP-CD3, APC-CD56, FITC-CD16, PE-
CD9, PE-CD49a, FITC-NKG2D (Miltenyi Biotec). FITC-conjugated, PE-
conjugated, PerCP-conjugated, and APC-conjugated isotype mAbs were 
used as controls. After physical parameter setting (Forward and Side 
Scatter) total lymphocytes were identified as CD45+CD14- cells and gated 
for further assessment for CD3- and CD56+ cells. CD16 expression was 
evaluated on CD3-CD56+ (total NKs) gated cells. Finally, the expression 
of the decidual markers CD9 and CD49a, and the NKG2D activatory 
marker was evaluated both on total and CD56brightCD16- NKs. For 
intracellular cytokine detection, 1x106 PBMCs from PB (HC and 
patients), TUM and ADJ tissues were cultured overnight in RPMI 1640 
supplemented with 10% heat-inactivated FBS (EuroClone), Pen/Strep, 
and IL-2 (100 U/ml; R&D Systems, Minneapolis, MN) at 37°C and 5% 
CO2. Cells were stained for NK cell surface markers, as already 
described, washed with PBS 1X and treated with Cytofix/Cytoperm 
fixation and permeabilization kit (BD) for 10 minutes at 4°C. Cells were 
then washed in PBS and stained with directly conjugated antibodies 
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(listed in Table 4 A) for 30 minutes. For indirect staining, cells were 
incubated for 1 hour at 4°C with primary unlabeled antibodies (listed in 
Table 4 B), washed and then stained with secondary labeled antibody 
(4°C, 30 minutes, dark). The fluorescence of each antibody was set on its 
appropriate isotype control and for indirect staining the secondary 
antibody alone was used as a negative control.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
A)  Direct staining 
 
 
	
B)  Indirect staining 
	
Primary 
Antibody 
Primary 
Antibody 
Specie 
Company Secondary 
Antibody 
Secondary 
Antibody 
Fluorochrome 
Company 
ANGIOGENIN	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
ANGIOPOIETIN	1	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
TIMP-1	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
TIMP-2	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
MMP-9	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
STAT-3	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
Phospho	STAT-3	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
STAT-5	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
Phospho	STAT-5	 Rabbit	anti-
human	
Abcam	 Goat	anti-
rabbit	
PE	 R&D	
	
	
	
	
	
Antigen Clone	 Fluorochrome Company	
VEGF	 23410	 PE	 R&D	
IL-8	 6217	 PE	 R&D	
MCP-1	 2H5	 PE	 Biolegend	
Table 4 – Antibody for Intracellular staining (Flow Cytometry) – A) anti-human directly 
conjugated antibodies used for FACS analysis; B) Primary and secondary antibodies exploited for 
indirect FACS staining. 
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4.6 Secretomic analysis of tumor-associated NKs 
Secretomic studies used 99% pure FACS-sorted NKs (CD3-
CD56+), isolated from total PBMCs from healthy controls and CRC PB, 
obtained as above.  
CRC-TANKs and NK cells from controls were transferred for 24 hours in 
FBS free RPMI 1640 to obtain conditioned media. After 24 hours, 
supernatants were collected, centrifuged to deplete residual dead cells and 
debris and concentrated using the Concentricon devices (Millipore, 
Temecula, CA) with a 3kDa membrane pore cut-off (conditioned media; 
CM). The ability of CRC TANKs to release pro-angiogenic factors was 
assessed by secretomic analysis, using the Human Angiogenesis Array 
C1000 (RayBiotech, Inc., Norcross GA). A full list for the spotted 
detection antibodies is available at web site www.abcam.com. Briefly, 
following membrane blocking for 30 minutes using the buffer provided 
by the kit, an equal amount of HC and TANK CM concentrated was 
diluted up to 1 mL with blocking buffer 1X and incubated overnight with 
membranes. Membranes were then washed to remove unbound material 
and incubated with a biotinylated antibody cocktail for 2h at room 
temperature. Membranes were washed and incubated with the HRP-
streptavidin concentrate for 2 hours. Following a washing step, 
chemiluminescent detection reagents were added. Luminescent signals 
were captured by exposure to Amersham Hyperfilm. Arrays were scanned 
into a computer and optical density measurements were obtained with 
National Institutes of Health ImageJ software. 
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4.7 NK degranulation assay 
CD107a expression on NK cells was measured to assess NK cell 
degranulation. PBMCs, isolated from peripheral blood, either from CRC 
patients or healthy controls, as well as from CRC adjacent normal and 
tumor tissues, were incubated with or without K562 cells in 200µL at 
37°C, 5% CO2, in 1:5 effector/target ratio. K562 cells are a human 
erythroid leukemia cell line expressing low levels of MHC class 1 widely 
used for the cytolysis assay. Following 4-hour culture, cell mixture was 
stained with mAbs against CD45-FITC, CD14-PE CD3-PerCP, CD56-
APC. Total lymphocytes were gated as CD45+CD14- cells, and NK cells 
were further counted as CD45+CD3-CD56+ cells. To determine the 
CD107a expression of NK cells, CD107a positive rate of CD3-CD56+ NK 
cells was analyzed. Killing efficiency was normalized to resting NK cells 
(peripheral blood, adjacent and tumor tissues, without the presence of 
K562 cells) for patients as compared to healthy controls. 
 
4.8 Protein extraction and pathscan sandwich immunoassay 
The PathScan Intracellular Signaling array kit (Cell Signaling 
Technology, Danvers, MA) was used, according to the manufacturer’s 
instructions, to detect the activation of intracellular signaling pathways. 
Briefly, NKs isolated as previously described from healthy donors and 
CRC patients were lysed in 1X Cell Lysis buffer. Following membrane 
blocking for 15 minutes using the buffer provided by the kit, 25 µg of 
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total protein lysates were added to each well and incubated for 2 hours at 
RT. Membranes were then washed for 5 times and then incubated with 
the detection antibody cocktail provided by the kit for 1 hour at RT. 
Following a washing step, HRP-linked streptavidin was added to each 
well and incubated for 2 hours at room temperature. Membranes were 
then washed and then chemiluminescent detection reagents were added 
and exposed to film for 2–30 sec. Arrays were scanned into a computer 
and optical density measurements were obtained with National Institutes 
of Health ImageJ software. 
 
4.9 Endothelial cell proliferation by CRC infiltrating NK derived 
conditioned media 
103 umbilical vein endothelial cells (HUVECs) (Promocell, 
Heidelberg, Germany) were grown on 1% gelatin-coated 96 well tissue 
culture plates in M199 growth medium (Sigma-Aldrich, St Louis, MO, 
USA), supplemented with heat inactivated 10% FBS (Sigma-Aldrich), 2 
mM glutamine (Gibco-Life Technologies, Thermo Fisher Scientific, 
Waltham, MA, USA), 100 µg/ml heparin sodium salt (Sigma-Aldrich), 10 
µg/ml hydrocortisone (Sigma-Aldrich), 10 ng/ml endothelial growth 
factor (EGF), 10 ng/ml acid and basic fibroblast growth factor (aFGF, 
bFGF) (Peprotech, Rocky Hill, NJ, USA). After cell adhesion, medium 
was replaced with 100 uL of fresh medium, containing equal amount of 
NK CM and cultured up to 48 hours at 37°C, 5% CO2. The 1-(4,5-
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dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) reagent (Sigma 
Aldrich) was added to a final concentration of 0.5 mg/ml to each well.  
Following 3 hours incubation at 37° C, medium was removed and 
formazan crystals were dissolved with 100 µl of DMSO. Absorbance was 
read at 570 nm in a micro-plate reader SpectraMax M2 (Molecular 
Devices, Sunnyvale CA). 
 
4.10 Chemotaxis and Morphogenesis on Human Umbilical Vein 
Endothelial Cell 
Conditioned media (CM) were obtained from PB (either from 
healthy age-matched controls or CRC patients), normal adjacent and 
tumor tissues FACS-sorted NK cells, as above. We evaluated the ability 
of NK-derived CM to induce endothelial cells recruitment using the 
Boyden chamber assay. 5x104 human umbilical vein endothelial cells 
(HUVECs; Promocell, Heidelberg, Germany) were placed onto the upper 
compartment of a Boyden chamber apparatus. A 10-µm pore size 
polycarbonate filter, pre-coated with collagen I (50 µg/ml), was placed as 
an interface between the upper and lower chamber. CM obtained from 
HC (healthy controls), PB (peripheral blood of CRC patients), ADJ 
(adjacent tissue) and TUM (tumor tissue) sorted NK cells were used as a 
chemoattractant, while serum free RPMI 1640 and 10% FBS 
supplemented RMPI 1640 were used respectively as a negative and 
positive controls. Following 6 hours of incubation at 37°C and 5% CO2, 
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the filters were recovered, and the cells migrated to the lower filter 
surface stained with 4',6-diamidino-2-phenylindole (DAPI; Sigma-
Aldrich) finally counted in a double-blind manner in five consecutive 
fields per filter, with a fluorescence microscope (Zeiss, Oberkochen, 
Germany).  
When plated on reconstituted basement membrane layer 
(matrigel), endothelial cells are able to induce the formation of a capillary 
network in the presence of a pro-angiogenic stimulus. We used NK CM to 
assess their ability to induce morphogenesis on matrigel (BD) layered 
human umbilical vein endothelial cells (HUVECs). 5x104 HUVE cells 
were seeded on a 10 mg/mL matrigel pre-coated 24 well plate and 
exposed on equal amount of NK CM obtained from HC, PB, adjacent and 
tumor tissue samples for 6 hours at 37°C and 5% CO2. After six hours, 
the network formation was detected with an inverted microscope (Zeiss). 
Master segment numbers and length were quantified using ImageJ 
software and the angiogenesis analyser tool. 
 
4.11 Cell adhesion assay in vitro 
HUVECs (3x103 cells) were exposed to NK derived CM and seeded in a 
48 wells plate pre-coated for 45 min with fibronectin (2 µg/ml). After 90 
min incubation, the supernatants were removed and cells were washed 
with PBS. Cells were fixed with 4% paraformaldehyde and stained with 
DAPI. Assays were performed in triplicates wells. Fifteen microscope 
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fields were randomly selected from three wells for each treatment to 
count the number of adherent cells. 
 
4.12 Flow Cytometry and Statistical Analyses 
Flow cytometry analyses were performed using BD FACSDiva (v6.1.2) 
and FlowJo (v7.2.5) software. Statistical analyses were performed using 
the GraphPad Prism5 statistics and graphing program (GraphPad 
Software, San Diego, CA). Two-tailed t tests were used for comparison of 
paired data sets and quartile localization for population distribution or 
one-way ANOVA for multiple data sets, and quartile localization for 
population distribution. For the morphogenesis analysis, master segment 
number and length were quantified using the ImageJ software and the 
angiogenesis analyser tool. Data obtained with secretomic and pathscan 
immunoassay were quantified using the ImageJ software and the Dot Blot 
analyser tool. 
 
	 
 
 
 
 
 
 
 
 
 
Results 
 
 
 
 
 
	 36	
5. RESULTS 
5.1 CD56+CD16- NK cells represents the predominant subset within 
tumor tissues  
Initial flow cytometric analysis of PBMC from HC and CRC 
patients was performed to evaluate NK cell subset distribution (Figure 10 
A). We observed that NK cells represent 0.1% to 3% of the whole CD45+ 
leukocytes population within the tumors, 1% to 4% of adjacent tissue 
(ADJ), and 13% on average in the peripheral blood (Figure 10 B). An 
increased proportion of CD56+CD16− NK cells were found in ADJ 
(87.9%) and in TUM (94.3%) samples as compared with healthy donors 
(16.3%) and PB of CRC patients (4.46%), while the CD56+CD16+ 
cytotoxic NKs remain the predominant subset in peripheral blood samples 
from patients and HC (Figure 10 B).  
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Figure 10- Subset analysis of NK cells in healthy donors and CRC derived samples. A) number 
of NKs in peripheral blood of healthy controls (HC), non-oncologic patients with other bowel 
diseases (BD), CRC patients (PB), adjacent tissues (ADJ) and tumor biopsies (TUM). B) 
percentage of CD56+CD16+ and CD56+CD16- in HC, BD, PB, ADJ and TUM samples. Results are 
expressed as Mean±SEM. n= 4-50. Statistical analysis: one-way ANOVA ***=p<0.001 
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5.2 CRC-derived NK cells show an impairment of cytotoxicity 
compared with NK isolated from healthy controls 
We therefore investigated whether the induction of TINK/TANK 
phenotype in CRC correlates with impaired NK function. We found that 
NKG2D, a surface marker for NK cell activation, was significantly 
decreased in NK cells isolated from peripheral blood, adjacent normal and 
tumor tissues from patients with CRC (*P<0.05), as compared to healthy 
controls (Figure 11 A). NKG2D decreased expression on CRC NK cells 
correlates with impaired NK killing efficiency, as confirmed by the down-
regulated CD107a expression levels (Figure 11 B), a surface marker for 
NK cell degranulation, on clinical samples.  
 
 
 
 
 
 
 
 
Figure 11 Evaluation of cytotoxic activities of NK cells in healthy donors and CRC 
samples. TINKs and TANKs isolated from CRC adjacent and tumor tissue samples show A) 
decreased level of the activatory NKG2D molecule that is associated B) with functional 
impairment of their killing activity measured by flow cytometry analysis of CD107a levels. 
HC: NK isolated from peripheral blood of healthy controls, PB: NK isolated from peripheral 
blood of CRC patients. ADJ: NK isolated from adjacent tissues, TUM NK isolated from tumor 
biopsies. Results are expressed as Mean±SEM. n= 3-6. Statistical analysis: one-way ANOVA 
*=p<0.05; **=p<0.01  
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5.3 NKs isolated from CRC tissues show a decidual-like phenotype 
Given the similarities between CRC TINKs/TANKs with dNK, we 
evaluated whether NK from CRC samples were able to express the 
decidual NK markers CD9 and CD49a. We demonstrated that NK cells 
derived from CRC samples exhibit a decidual-like phenotype, showing 
increased expression for the dNK markers CD9 and CD49a, difference 
that is statistically significant when considering only CD56+CD16- subset 
(*P<0.05; **P<0.01; ***P<0.001) (Figure 12).  
A 
 
 
B 
Figure 12 Decidual-like phenotype evaluation of CRC NK cells The CD56+CD16- TINK and adjacent 
NK cells express higher levels of the CD9 (A) and CD49a (B) NK decidual markers as compared with 
those from peripheral blood NK cells (patients and healthy controls). HC: NK isolated from peripheral 
blood of healthy controls, PB: NK isolated from peripheral blood of CRC patients, ADJ: NK isolated 
from adjacent tissues, TUM NK isolated from tumor biopsies. Results are expressed as Mean±SEM. n= 
3-10. Statistical analysis: one-way ANOVA*=p<0.05; **=p<0.01, ***=p<0.001. 
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Similar results are also found on TINKs and TANKs from NSCLC 
patients, thus supporting the hypothesis of a decidual-like subset in solid 
tumors (Figure 13). 
 
  
 
 
5.4 CRC derived TANKs can release pro-angiogenic factors 
To further evaluate the pro-angiogenic properties of CRC derived 
NKs, we performed secretomic analysis using conditioned media from 
CRC patients and HC FACS sorted NKs, using commercially available 
membrane array kits. Since the limited percentage of NK cells in CRC 
biopsies, for molecular studies, we focused our attention on CRC derived 
Figure	 13	 Decidual-like phenotype evaluation of non small cell lung cancer (NSCLC) NK 
cells. According to our results obtained in CRC derived NKs, the CD56+CD16- TINK and 
adjacent NK cells express higher levels of the CD9 and CD49a decidual markers as compared with 
those from peripheral blood NK cells (patients and healthy controls). HC: NK isolated from 
peripheral blood of healthy controls, PB: NK isolated from peripheral blood of NSCLC patients, 
ADJ: NK isolated from adjacent tissues, TUM NK isolated from tumor biopsies. Results are 
expressed as Mean±SEM. n= 3-7. Statistical analysis: one-way ANOVA*=p<0.05; **=p<0.01, 
***=p<0.001. 
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TANKs, comparing them with NK cells isolated from healthy donors. 
Secretomic analysis revealed that CRC TANKs are able to release a wide 
array on pro-angiogenic factors, necessary for endothelial and 
inflammatory cell recruitment and proliferation (including GRO, MCP-1, 
ENA-78, EGF, I-309), as compared to HC. Among these, a strong up-
regulation was observed for Angiogenin, IL-8, TIMP-1 and TIMP-2, 
MMP-9, MCP-1, VEGF and Angiopoietin 1 (Figure 14). 
 
 
 
 
 
 
Figure 14  Secretome analysis by protein membrane arrays – peripheral blood NK cells isolated 
from CRC patients are able to release a wide array of pro-angiogenic factors as compared to healthy 
controls. Data obtained were quantified by ImageJ Dot Blot analysis software and factors that resulted 
highly up-regulated were selected to be validated. Orange bars: supernatants from healthy controls 
derived NKs, red bars: supernatants from peripheral blood NK cells isolated from CRC patients. 
Results are expressed as percentage over ctrl (HC). Statistical analysis: t-test *=p<0.05 
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Therefore, to validate these data we performed intracellular staining for 
cytokine detection using a multicolour flow cytometry approach. Our 
results confirm data obtained with secretomic analyses, showing a 
significant increase of selected cytokine and factor production by TANKs 
comparing them with NK isolated from healthy controls. To further 
investigate whether the production of pro-angiogenic factors by CRC 
derived TANKs may represent a relevant parameter to keep into 
consideration, we also included in our cohort non-oncologic patients with 
other bowel diseases (BD) (diverticulosis), showing that NK cells isolated 
from patients with BD patients produced comparable levels of pro-
angiogenic factors with that of healthy controls. On the contrary, a 
significant enhanced production of Angipoietin, IL-8, TIMP-1, TIMP-2, 
VEGF and MMP-9 was observed comparing CRC TANKs to BD NKs 
(Figure 15) (*P<0.05; **P<0.01; ***P<0.001).  
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Figure 15 Pro-angiogenic cytokines production by NK cells- Pro-angiogenic cytokines 
production was assessed by multiparametric flow analysis, confirming that peripheral blood NK 
cells isolated from CRC patients (PB CRC) can produce higher levels of selected cytokines 
compared with peripheral blood NK cells isolated from healthy donors (HC). In addition, CRC 
TANKs showed an increased production of pro-angiogenic molecules also when compared to NK 
isolated from patients with non-oncologic bowel diseases (PB BD). Results are expressed as 
Mean±SEM. n= 3-11. Statistical analysis: one-way ANOVA *=p<0.05; **=p<0.01, ***=p<0.001. 
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These data clearly demonstrate that a pro-angiogenic polarization occurs 
on peripheral blood CRC NKs, suggesting a systemic effect on NK cells 
from CRC patients. These data indicate a potential application of NK 
cells as potential clinical biomarkers of CRC.  
 
5.5 CRC TINK/TANKs Promote Angiogenesis-Associated Effects on 
Endothelial Cells (HUVECs)  
We further investigated whether CRC TINK/TANKs, showing a pro-
angiogenic phenotype in term of surface antigen expression and cytokine 
profiling, were effectively able to induce angiogenesis in-vitro. We found 
that conditioned media (CM) obtained from FACS sorted NK from CRC 
peripheral blood and tumor tissues are able to induce HUVE cell 
proliferation as compared with those from healthy controls (Figure 16). 
NT(M199)
NT(RPMI+M199)
HC
PB
TUM
 
Figure	 16	 Pro-angiogenic activity of NK cell derived conditioned media – induction of 
HUVEC proliferation. Supernatants from CRC NK cells induced endothelial cell proliferation 
after 48 hours of exposition. HC, serum free M199 medium supplemented with 30% of healthy 
controls derived NK supernatants. PB, serum free M199 medium supplemented with 30% of 
supernatants of CRC TANKs. TUM, serum free M199 medium supplemented with 30% of 
supernatants of CRC TINKs. Results are expressed as Mean±SEM. Statistical analysis: t-test 
*=p<0.05; **=p<0.01	 
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Migration is a crucial step in the angiogenic process, since endothelial 
cells are required to migrate from pre-existent vessels to the tumor site.  
CM from CRC patients NK cells, either from peripheral blood or tumor 
infiltrating, were able to recruit more endothelial cells as compared with 
those from HC, as confirmed by the Boyden Chamber migration assay 
(Figure 17).  
 
 
 
 
When cultured on a membrane-basement matrix layer, HUVE cells can 
from capillary-like structures in-vitro, mimicking the events occurring 
during the vessel lumen formation in-vivo. We found that CM from NK 
isolated from CRC peripheral blood and tumor tissues are able to more 
efficiently induce the formation of capillary-like structures in HUVE 
cells, as compare with those from HC (Figure 18). 
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Figure 17 Pro-angiogenic activity of NK cell derived conditioned media – induction of 
HUVEC migration. Supernatants from CRC NK cells induced endothelial cell migration. 
FBS−, serum-free medium as a negative control. FBS+, serum-free M199 with 1% L-glutamine, 
fibroblast growth factors (10 ng of acidic fibroblast growth factor plus 10 ng of basic fibroblast 
growth factor/ml), epidermal growth factor (10 ng/ml), heparin (0.1 mg/ml), and hydrocortisone 
(0.1 µg/ml). HC, serum free M199 medium supplemented with 30% of healthy controls derived 
NK supernatants. PB, serum free M199 medium supplemented with 30% of supernatants of CRC 
TANKs. TUM, serum free M199 medium supplemented with 30% of supernatants of CRC 
TINKs. Results are expressed as Mean±SEM of two independent experiments. Statistical 
analysis: t-test *=p<0.05; **=p<0.01 
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.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 - Pro-angiogenic activity of NK cell derived conditioned media – induction 
of capillary-like structure formation by HUVECs. Supernatants from TINK/TANK 
promote morphogenesis process on HUVE cells plated on a matrigel basement. K−, 
serum-free medium as a negative control. K+, serum-free M199 with 1% L-glutamine, 
fibroblast growth factors (10 ng of acidic fibroblast growth factor plus 10 ng of basic 
fibroblast growth factor/ml), epidermal growth factor (10 ng/ml), heparin (0.1 mg/ml), 
and hydrocortisone (0.1 µg/ml). HC, serum free M199 medium supplemented with 30% 
of healthy controls derived NK supernatants. PB, serum free M199 medium 
supplemented with 30% of supernatants of CRC TANKs. TUM, serum free M199 
medium supplemented with 30% of supernatants of CRC TINKs. Results are expressed 
as Mean±SEM of two independent experiments. Statistical analysis: One-way ANOVA 
*=p<0.05; **=p<0.01; ***=p<0.001  
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Finally, we demonstrated that TINK/TANK CM can significantly 
increase HUVEC adhesion on a fibronectin matrix (Figure 19) comparing 
with HC-NK CM (***P<0.001).  
 
 
 
 
 
 
 
 
 
 
 
5.6 CRC TANK derived conditioned media are able to induce 
angiogenesis by activating diverse intracellular pathways in human 
endothelial cells 
By using the PathScan Intracellular Signaling array kit to simultaneously 
detect the phosphorylation/activation of diverse pathways, we observed 
that conditioned media derived from FACS sorted TANKs are able to 
activate several pro-angiogenic pathways in HUVE cells. After 24 hours, 
phospho-(AMP-activated protein kinase α (AMPKα)), phospho-Glycogen 
Synthase Kinase 3β and phospho-P70 S6 Kinase were up-regulated in 
Figure 19  Pro-angiogenic activity of NK cell derived conditioned media – promotion of 
HUVEC adhesion. Supernatants from TINK/TANK promote adhesion of HUVE cells plated 
on a fibronectin matrix. HC, serum free M199 medium supplemented with 30% of healthy 
controls derived NK supernatants. PB, serum free M199 medium supplemented with 30% of 
supernatants of CRC TANKs. TUM, serum free M199 medium supplemented with 30% of 
supernatants of CRC TINKs. Results are expressed as Mean±SEM of three independent 
experiments. Statistical analysis: One-way ANOVA ***=p<0.001 
	 48	
TANK CM exposed HUVECs compared with HC CM treated cells. 
Following 48 hours of exposition only phospho-AMPK and phosphor-S6 
ribosomal proteins were up-regulated in HUVE cells treated with TANK 
CM (Figure 20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 Intracellular Signaling activation in HUVEC treated with conditioned media 
derived by healthy controls and CRC TANK. Increased activation of several pathways, 
including AMPK, GSK3b, P70 S6 Kinase and S6 ribosomal protein was detected in HUVEC 
treated with CM from FACS sorted TANKs following 24hours and 48 hours of exposition. Data 
obtained were quantified by ImageJ Dot Blot analysis software. Orange bars: HUVECs exposed to 
CM derived from healthy control NK cells, red bars: HUVECs exposed to CM derived from 
TANKs. Results are expressed as percentage over ctrl (HC). Statistic analysis: t-student *=p<0.05  
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5.7 CRC TANKs showed diverse activated intracellular pathways 
compared with NKs isolated from healthy donors 
We speculate that the pro-angiogenic phenotype of CRC TANKs and 
functions might be correlated with the activation of different molecular 
pathways able to regulate the transcription of pro-angiogenic molecules. 
To verify our hypothesis, we use the PathScan Intracellular Signaling 
array kit to simultaneously detect the phosphorylation/activation of 
diverse intracellular signaling.  
Our data showed an increased phosphorylation/activation of several 
intracellular pathways in CRC TANKs compared with healthy control NK 
cells. Among these, several molecules involved in the regulation of NK 
metabolism (AMP-activated protein kinase α (AMPKα) and Pyruvate 
dehydrogenase lipoamide kinase isozyme 1 (PDK1)) and cytotoxic 
functions (Phosphatase and tensin homolog (PTEN), Protein kinase B 
(AKT) and Protein Kinase B (mTOR)) (Figure 21) resulted more 
activated in CRC TANKs than in healthy control NKs.  
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We further evaluated the expression and activation of STAT-3 and 
STAT-5, two molecules that have been reported to be related with NK 
cell ability to induce tumor angiogenesis and to sustain tumor progression 
[41, 42]. By using a multicolour flow cytometry approach, we observed a 
statistically significant increase of STAT-3 and STAT-5 expression and 
activation/phosphorylation in CRC TANKs compared not only with 
Figure 21 Intracellular Signaling activation in CRC TANKs. NKs isolated from CRC patients’ 
peripheral blood showed an increased activation of several pathways, including AMP-activated 
protein kinase α (AMPKα) and Pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1), 
Phosphatase and tensin homolog (PTEN), Protein kinase B (AKT) and mammalian target of 
rapamycin (mTOR) Data obtained were quantified by ImageJ Dot Blot analysis software. Orange 
bars: NKs from healthy controls, red bars: NK cells isolated from peripheral blood of CRC 
patients. Results are expressed as percentage over healthy control (HC).   
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healthy donors derived NK cells, but also with NK cells isolated from 
non-oncologic BD patients (Figure 22).  
 
 
Figure	 22	 STAT-3 and STAT-5 expression levels and activation in NK cells- Peripheral 
blood NK cells isolated from CRC patients (PB CRC) showed higher levels of STAT-3 as far as 
STAT-5 compared with peripheral blood NK cells isolated from healthy donors (HC) and with 
NKs isolated from patients with non-oncologic bowel diseases (PB BD). Results are expressed as 
Mean±SEM. n= 3-11. Statistical analysis: One way ANOVA *=p<0.05; **=p<0.01, ***=p<0.001.  
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6. DISCUSSION 
Tumors represent an extremely heterogenic “scenario” where several 
“actors” interact each other inducing the complex network of tumor 
microenvironment (TME) [66, 75]. As a consequence of their plasticity, 
TME is able to shape immune cell functions that can acquire tumor-
promoting features like anergy [76] and induction of  angiogenesis [77]. 
The angiogenic switch has been described for diverse immune cells 
within the TME [76], while acquisition of angiogenic-features by NKs 
have been poorly investigated in the tumor context. The pro-angiogenic 
CD56brightCD16-VEGFhighPlGFhighIL-8+IFNγlow NK cell subset was 
identified in patients with non small cell lung cancers  [30, 33], placing 
NKs as a novel orchestrator in the inflammatory angiogenic switch in 
tumors. TGFβ, a major immunosuppressive cytokine in the TME act and 
a pro-angiogenic switcher on cytolytic NK both at tissue and peripheral 
levels. Based on these novel findings on NSCLC, we moved to CRC to 
investigate whether induction of pro-angiogenic phenotype and functions 
on peripheral blood and tissue infiltrating NKs my occur in other solid 
cancers. We confirmed previous data on NK subset distribution in CRC 
[74] and using a larger sample size we demonstrated that in normal 
adjacent and CRC tissues, NK cells are polarized towards the 
TINK/TANK CD56+CD16- phenotype. 
NK cells represent 0.1% to 3% of the whole CD45+ leukocytes population 
within the tumors, 1% to 4% of adjacent tissues, and 13% on average in 
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the peripheral blood. Our results on the low percentage of TINKs in CRC 
are supported by previous studies that have investigated NK infiltration in 
colorectal tumors and the possible correlations with the clinical outcome.  
Contrasting results, correlating the number of infiltrating NKs and CRC 
patients outcome are present in the literature. Sandel et al. [28], and 
Halama et al. [72] observed a low percentage of NKs within CRC tissues 
that appears to exert a marginal role for NKs in tumor regulation [28, 62]. 
On the contrary, the relevance of NK on patient outcome were suggested 
by Gulubova et al. and Menon et al. which revealed that NKs, despite 
their low number, play a crucial role in the immune surveillance in 
colorectal cancer patients, showing that NK infiltration of tumor tissues is 
associated with a reduced risk of relapse and prolonged survival [78, 79]. 
Marechal et al., demonstrated that CD56+ cells and mainly NK cells are 
the major effector of ADCC related-cetuximab activity, suggesting that 
CD56+ cells infiltrate in primary colorectal adenocarcinoma may 
represent a relevant parameter to monitor to predict the response of 
mCRC patients treated with first-line cetuximab-based chemotherapy 
[80]. Sconocchia et al highlight the relevance of the cross talk between 
intra-tumor NK cell infiltration and other immune cells, including T 
lymphocytes within CRC. They show that NK cells positively influenced 
the clinical outcome of CRC patients by enhancing the protective role of 
tumor-infiltrating CD8+ T cell [62]. In agreement with this evidence, Van 
Den Broeke et al reported that NK/dendritic cell (DC) interaction 
	 53	
represent an interesting mechanism against cancer, suggesting in an in 
vivo model of colorectal cancer that mature DCs may stimulate CD4+ T 
cells that could in turn directly activate NK cells through IL-2 secretion 
[81]. Confirming the phenotype and function similarity between dNK and  
NSCLC/CRC TINK/TANKs, we found that in tumor and normal adjacent 
tissues, CRC NKs exhibit increased expression of the dNK markers CD9 
and CD49a [36, 37, 82], suggesting that the polarization towards a 
TINK/TANK phenotype may represent a crucial feature of solid tumors. 
These data are supported by Levi et al., which recently reported that a 
clear and significant enrichment of the CD56brightCD16dim NK subset 
expressing decidual surface markers occurs in a small cohort of CRC, 
breast and melanoma patients [83]. Several studies have showed that 
NKG2D engagement is crucial for NK cell activation and that decreased 
NKG2D expression is associated with impaired NK cell function in 
gastric cancer [84], metastatic melanoma [85] and breast cancer [32], 
resulting in cancer immune-escape. We showed that NKG2D expression 
is decreased in peripheral blood, adjacent normal and tumor tissues of 
CRC patients as compared to healthy controls. This different pattern of 
NKG2D expression correlates with impaired cytotoxicity, as confirmed 
by the degranulation assay, showing decreased CD107a levels in all CRC 
samples. We suggest that the alteration in NKG2D receptor repertoire and 
impairment of NK lytic activity might reflect the polarization that induce 
NK to sustain tumor progression through angiogenesis induction. Our 
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data are supported by Gharagozloo et al and Rocca et al, which also 
showed a significant reduction in the percentage of NKG2D+NK cells as 
well as NKG2D mRNA expression in peripheral blood of metastatic 
colon cancer patients [74, 86], suggesting that the decreased expression of 
activating NKG2D receptor in CRC might represent a relevant marker in 
the clinic. NK cytotoxicity impairment in CRC TANKs was also 
confirmed by the alteration of intracellular pathways, including 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and 
AMP-activated protein kinase (AMPK) signaling, that have been reported 
to negatively regulate NK cytotoxicity. Briercheck et al showed up-
regulation of PTEN in resting CD56bright NK cells [87]. Leong et al 
suggested PTEN as a key regulator of NK killing functions by promoting 
IFN-γ production in response to cytokine stimulation and migration to 
distal tumor sites [88]. Likewise, AMPK activation has been associated 
with the reduction of NK cytotoxicity, cytokine secretion, proliferation, 
and telomerase expression [89]. Extensive alterations in serum cytokine 
repertoire have been reported in CRC patients, suggesting their direct 
contribution to cancer progression [90, 91]. These studies highlighted 
their implication in the clinic and their potential use as targets for the 
design of novel therapeutic approaches or as biomarkers able to 
strengthen the prognosis of the Immunoscore [92]. According with these 
findings, we observed an increase in several cytokines and chemokines 
release by CRC TANKs, including VEGF, IL-8, MMP-9, TIMP-1 and 
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TIMP-2, angiogenin and angiopoietin 1, that could contribute to 
angiogenic induction in CRC. The study by Asfaha et al supports this 
observation: they showed an up-regulation of IL-8 expression in CRC 
tissue compared with adjacent healthy colonic tissue, demonstrating that 
IL-8 can exacerbate inflammation and accelerates colon carcinogenesis 
by promoting tumor angiogenesis [93]. Likewise, VEGF up-regulation 
has been reported CRC tissue and positively correlates with advanced 
tumor stage as well as positive lymph node and liver metastasis [94]. 
VEGF plasma levels are higher in CRC patients compared with healthy 
donors and have been correlated with a negative outcome [95]. Secreted 
VEGF is also able to activate STAT-3 signaling in CRC tumors [96] 
promoting cancer progression and induces angiogenesis by acting directly 
or indirectly on endothelial cells [97]. Based on our results and literature 
data, we hypothesized a role for NK cells in CRC progression acting by 
angiogenesis induction, and we observed that FACS sorted NK derived 
conditioned media (CM) from CRC TINK/TANKs are able to promote 
angiogenesis in vitro, by inducing HUVEC proliferation after 48 hours of 
exposition. This phenomenon is associated with the increase of S6 
ribosomal Protein levels that represents a positive regulator of endothelial 
cell proliferation [98]. TANK CM also induces the formation of capillary 
like structures and promotes endothelial cell migration and adhesion by 
inducing AMPK and GSK3β phosphorylation. The correlation between 
NK and angiogenesis has been also demonstrated by previous work on 
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NSCLC, obtaining comparable results [30, 33]. The relevance of NK in 
tumor angiogenesis have also been highlighted by Gotthard et al, that 
clarified in an in-vivo model of RMA-S lymphoma cells and v-abl 
transformed tumor the crucial role of STAT-5 pathway [41, 42]. They 
demonstrated that Stat5∆/∆Ncr1-iCreTg-Vav-Bcl2 mice failed to control 
tumor growth and produced increased VEGF levels [41, 42]. In 
accordance with these findings, we also investigated the percentage of 
total STAT-5 and P-STAT5 positive NK cells, hypothesizing the same 
mechanism of action. In contrast to what we expected, we found 
increased levels of STAT-5 in TANK compared with NK from healthy 
donors. Also P-STAT3 levels, another key regulator of NK development, 
activation and target cell killing, were up-regulated in tumor derived NK 
compared with healthy controls. Persistent activation of STAT-3 has been 
reported to enhance tumor cell proliferation, survival and invasion while 
suppressing anti-tumor immunity by inducing NF-κB phosphorylation 
and up-regulating several molecules including IL-8, MMP-9, VEGF and 
MCP-1 [99]. The induction of STAT associated pathways has been 
reported in several tumors and among its activators, cytokines and 
Tyrosine Kinase Receptors signaling have been reported to play a crucial 
role [100]. Küçük et al also showed that activation of STAT3 and 
STAT5B due to activatory mutations occurs frequently in NK/T-cell 
lymphomas [101]. 
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7. CONCLUSIONS 
 
Our study sheds light on the role of NKs in tumor progression, that 
a part from immunosuppression, includes induction of angiogenesis. Our 
results clearly demonstrate that pro-angiogenic phenotype and functions 
of TINK/TANK might represent a common feature of solid tumors that 
not only contribute, but also orchestrate other TME components to 
support tumor progression by enhancing tumor angiogenesis. In this view, 
NK cells and their associated cytokines might be considered for future 
studies aimed at investigation their potential application as prognostic 
parameter as well as clinical biomarkers, to early detect tumors or for 
patients’ follow up. Therefore, the identification of NKs in the blood as 
“predictors” of those infiltrating solid cancers, allow the extension of the 
recent concept of immunoscore to the peripheral level suggesting the 
possibility of an inflammoscore.  Finally, CRC NK cells may represent a 
potential therapeutic target for agents able to restore the cytotoxic 
phenotype/function of TINK/TANKs or interfere with their altered 
polarization state. 
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Figure 23 – Representative scheme of our findings 
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